Ignacio Moraleda

Ignacio Moraleda

Auto-generated profile, based on publicly available information

Ignacio Moraleda

Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805, Alcalá de Henares, Madrid, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LWLi Wang
Li Wang
GEGerard Esteban
Gerard Esteban
MOMasaki Ojima
Masaki Ojima
ÓBÓscar Bautista
Óscar Bautista
TITsutomu Inokuchi
Tsutomu Inokuchi
MUMercedes Unzeta
Mercedes Unzeta

1 April 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EAEhab D. AlFadly
Ehab D. AlFadly
PEPerihan Elzahhar
Perihan Elzahhar
ATAnna Tramarin
Anna Tramarin
SESalwa Elkazaz
Salwa Elkazaz
HSHossam Shaltout
Hossam Shaltout
ABAhmed S.F. Belal
Ahmed S.F. Belal

1 September 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
ÓBÓscar Bautista
Óscar Bautista
SHStefanie Hagenow
Stefanie Hagenow
APAlejandra Palomino‐Antolin
Alejandra Palomino‐Antolin
VFVictor Farré
Victor Farré
LILhassane Ismaili
Lhassane Ismaili
HSHolger Stark
Holger Stark

16 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RCRicardo Caballero
Ricardo Caballero
PDPablo Dolz-Gaitón
Pablo Dolz-Gaitón
RGRicardo Gómez
Ricardo Gómez
IAIrene Amorós
Irene Amorós
ABAdriana Barana
Adriana Barana
EDEva Delpón
Eva Delpón
Both increase and decrease of cardiac inward rectifier current (IK1) are associated with severe cardiac arrhythmias. Flecainide, a widely used antiarrhythmic drug, exhibits ventricular proarrhythmic effects while effectively controlling ventricular arrhythmias associated with mutations in the gene encoding Kir2.1 channels that decrease IK1(Andersen syndrome). Here we characterize the electrophysiological and molecular basis of the flecainide-induced increase of the current generated by Kir2.1 channels (IKir2.1) and IK1recorded in ventricular myocytes. Flecainide increases outward IKir2.1generated by homotetrameric Kir2.1 channels by decreasing their affinity for intracellular polyamines, which reduces the inward rectification of the current. Flecainide interacts with the HI loop of the cytoplasmic domain of the channel, Cys311 being critical for the effect. This explains why flecainide does not increase IKir2.2and IKir2.3, because Kir2.2 and Kir2.3 channels do not exhibit a Cys residue at the equivalent position. We further show that incubation with flecainide increases expression of functional Kir2.1 channels in the membrane, an effect also determined by Cys311. Indeed, flecainide pharmacologically rescues R67W, but not R218W, channel mutations found in Andersen syndrome patients. Moreover, our findings provide noteworthy clues about the structural determinants of the C terminus cytoplasmic domain of Kir2.1 channels involved in the control of gating and rectification.

24 June 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Cristobal De Los RiosCristobal De Los Rios
Cristobal De Los Rios
Javier EgeaJavier Egea
Javier Egea
JMJosé Marco-Contelles
José Marco-Contelles
Rafael LeónRafael León
Rafael León
Abdelouahid SamadiAbdelouahid Samadi
Abdelouahid Samadi
Alejandro RomeroAlejandro Romero
Alejandro Romero